摘要
目的观察生长抑素注射剂治疗胰腺炎患者的临床疗效及安全性。方法将98例胰腺炎患者随机分为对照组和试验组,每组49例。对照组给予肠胃减压,保持体内酸碱、电解质平衡,抑制胰腺分泌并进行营养输入等基础治疗;试验组在对照组治疗的基础上,给予生长抑素每次3 mg,qd,静脉滴注。2组患者均治疗14 d。比较2组患者的临床疗效,二胺氧化酶(DAO)、尿淀粉酶(UAMY)和血浆内霉素(PE)的水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为85.71%(42例/49例)和67.35%(33例/49例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的DAO分别为(2.68±0.73)和(4.29±1.13)ng·L^-1,UAMY分别为(6.57±1.53)和(9.82±1.96)U·L^-1,PE分别为(3.31±0.83)和(5.34±1.21)EU·mL^-1,差异均有统计学意义(均P<0.05)。2组患者的药物不良反应均以心律不齐、呕吐和恶心为主。试验组和对照组的总药物不良反应发生率分别为12.24%和28.57%,差异有统计学意义(P<0.05)。结论生长抑素注射剂治疗胰腺炎患者的临床疗效确切,且安全性较高。
Objective To observe the clinical efficacy and safety of somatostatin injection in the treatment of patients with pancreatitis.Methods A total of 98 patients with pancreatitis were randomly divided into control and treatment groups with 49 cases per group.The control group was given basic treatment such as gastrointestinal decompression,maintaining acid-base and electrolyte balance,inhibition of pancreatic secretion and nutrition input.The treatment group received somatostatin 3 mg per group,qd,intravenous drip,on the basis of control group.Two groups were treated for 14 days.The clinical efficacy,the levels of diamine oxidase(DAO),urine amylase(UAMY)and plasma endotoxin(PE),and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 85.71%(42 cases/49 cases)and 67.35%(33 cases/49 cases)with significant difference(P<0.05).After treatment,the main indexes of treatment and control groups were compared:DAO were(2.68±0.73)and(4.29±1.13)ng·L^-1,UAMY were(6.57±1.53)and(9.82±1.96)U·L^-1,PE were(3.31±0.83)and(5.34±1.21)EU·mL^-1,the differences were statistically significant(all P<0.05).The adverse drug reactions of two groups were arrhythmia,vomiting and nausea.The incidences of total adverse drug reactions were 12.24% and 28.57% with significant difference(P<0.05).Conclusion Somatostatin injection has a definitive clinical efficacy and safety in the treatment of patients with pancreatitis.
作者
王双养
周医宾
唐跃华
WANG Shuang-yang;ZHOU Yi-bin;TANG Yue-hua(Department of Gastroenterology,Zhoushan Traditional Chinese Medicine Hospital,Zhoushan 316000,Zhejiang Province,China;Department of Gastroenterology,Zhoushan Branch of Shanghai Ruijin Hospital,Zhoushan 316000,Zhejiang Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2020年第15期2193-2195,共3页
The Chinese Journal of Clinical Pharmacology
关键词
生长抑素注射剂
胰腺炎
安全性评价
somatostatin injection
pancreatitis
safety evaluation
